Hayley Crawford, PhD, and Carl Marci, MD, discuss how their specific industries have developed new innovations in response to the COVID-19 pandemic.
The disease area that has received the most attention, time, and financial support during the last two years has been COVID-19. There has been tremendous emphasis on addressing the new challenges presented during this global pandemic, including rapid vaccine development, effective patient treatments, supplying reliable testing methods, and providing equitable healthcare access for diverse populations. Participate to learn about innovations that have been recently developed for the fight against SARS-CoV-2.
Dr. Hayley Crawford describes Integral Molecular's catalog of 70+ SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotypedviruses) that enable researchers to rapidly test neutralization by antibodies and sera in a safe BSL-2 environment. The presentation covers Integral Molecular's RVP offerings that include Omicron subvariants BA.1 and BA.2,and neutralizing antibody controls. Dr. Crawford also describes additional research solutions from Integral Molecular such as epitope mapping and antibody specificity profiling and how these tools together meet the most recent FDA recommendations for variant testing of vaccines and therapeutic antibodies.
Dr. Carl Marci explores the pandemic from a different viewpoint. As has becoming increasingly clear, the effects of isolation at various stages of the COVID-19 pandemic have resulted in increased stress and anxiety in numerous populations. Using real-world data, Dr. Marci explains how real-world trends and diagnoses rates of anxiety and depression can be used to understand mental health before and after the beginning of the pandemic. Dr. Marci also highlights how real-world data can be used to understand mental health trends and patient outcomes.
Presenters
Hayley Crawford
Hayley Crawford is the Virology Project Leader at Integral Molecular and manages the company’s extensive Reporter Virus Particle (RVP) portfolio. She spearheads all aspects of the SARS-CoV-2 RVP product cycle—from product development through manufacturing and quality control—for current and emerging strains. Prior to joining Integral Molecular, Dr. Crawford was a postdoctoral researcher at Oxford University, where she worked on designing HIV vaccines using CD8+ T cell epitope constructs. She obtained her PhD from Oxford University and has over a decade of experience in virology and immunology.
Carl Marci
Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1.
Sponsor
Integral Molecular
OM1
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
HealthEconomics.com
HealthEconomics.com is the world’s largest Connected Community™ for Value, Evidence and Access in the life sciences industry.
HealthEconomics.com provides a single global link to the health economic and outcomes research (HEOR), real-world evidence (RWE), and Market Access (MA) stakeholder communities. Since 1993, we have provided unparalleled access to drive business, improve knowledge, and connect researchers and payer decision-makers world-wide.
Our 27,000 engaged readers rely on HealthEconomics.com as the most reliable, credible and curated digital hub for the latest news, insights, educational opportunities, and industry benchmarks in HEOR, RWE and MA. Our advertisers, numbering more than 500 with a 91% retention rate, depend upon HealthEconomics.com for best-in-class global brand awareness and business development solutions. Our aim is to connect people with expert-driven content and resources — all in one place — with the corporate mission to advance communication about healthcare value.
